Avita Medical Ltd (RCEL)
Official siteHEALTHCARE • MEDICAL DEVICES • NASDAQ
Market Cap: $491.10M
Last updated: Nov 17, 2026 at 11:05 AM ET
Avita Medical Ltd (RCEL) Earnings: Report Dates and Results
Avita Medical (RCEL) is expected to report earnings on Feb 10, 2027. In the quarter ended Sep 30, 2026, Avita Medical reported EPS of -$0.20, above the -$0.29 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
RCEL has an expected report date of Feb 10, 2027.
RCEL Earnings Call
The latest RCEL earnings call transcript on file is labeled 2026Q3.
Read the 2026Q3 transcriptEarnings History
Of the 28 quarters below that had an estimate, RCEL beat 14 and missed 14. Revenue for the quarter ended Sep 30, 2026 was $26.11M, up 53.0% from $17.06M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | -$0.20 | -$0.29 | -$0.36 - -$0.23 | +31.03% | Beat | N/A | 4 | 4 up, 0 down | Nov 5, 2026 | $26.11M |
| Jun 30, 2026 | -$0.25 | -$0.39 | -$0.46 - -$0.31 | +35.90% | Beat | N/A | 4 | N/A | Aug 6, 2026 | $21.70M |
| Mar 31, 2026 | -$0.48 | -$0.38 | -$0.50 - -$0.27 | -26.32% | Miss | N/A | 4 | 3 up, 0 down | May 14, 2026 | $19.25M |
| Dec 31, 2025 | -$0.54 | -$0.55 | -$0.77 - -$0.36 | +1.82% | Beat | N/A | 6 | 2 up, 1 down | Feb 12, 2026 | $17.62M |
| Sep 30, 2025 | -$0.71 | -$0.45 | -$0.66 - -$0.17 | -57.78% | Miss | N/A | 6 | 0 up, 5 down | Nov 6, 2025 | $17.06M |
| Jun 30, 2025 | -$0.38 | -$0.26 | -$0.48 - -$0.25 | -46.15% | Miss | N/A | 5 | 1 up, 0 down | Aug 7, 2025 | $18.42M |
| Mar 31, 2025 | -$0.83 | -$0.51 | -$0.68 - $0.02 | -62.75% | Miss | N/A | 6 | 1 up, 1 down | May 8, 2025 | $18.51M |
| Dec 31, 2024 | -$0.70 | -$0.74 | -$0.98 - -$0.30 | +5.97% | Beat | N/A | 7 | 0 up, 3 down | Feb 13, 2025 | $18.41M |
| Sep 30, 2024 | -$0.62 | -$0.44 | -$0.50 - -$0.35 | -40.91% | Miss | N/A | 6 | 0 up, 0 down | Nov 7, 2024 | $19.55M |
| Jun 30, 2024 | -$0.91 | -$0.76 | N/A | -19.74% | Miss | N/A | 5 | 0 up, 0 down | Aug 8, 2024 | $15.20M |
| Mar 31, 2024 | -$1.10 | -$0.73 | -$0.73 - -$0.26 | -50.68% | Miss | N/A | 5 | 0 up, 0 down | May 13, 2024 | $11.10M |
| Dec 31, 2023 | -$0.43 | -$0.57 | N/A | +24.56% | Beat | N/A | 5 | 2 up, 0 down | Feb 22, 2024 | $14.20M |
| Sep 30, 2023 | -$0.53 | -$0.68 | N/A | +22.06% | Beat | N/A | 5 | 1 up, 0 down | Nov 9, 2023 | $13.64M |
| Jun 30, 2023 | -$0.63 | -$0.46 | N/A | -36.96% | Miss | N/A | 5 | 0 up, 0 down | Aug 10, 2023 | $11.75M |
| Mar 31, 2023 | -$0.55 | -$0.36 | N/A | -52.78% | Miss | N/A | 4 | 0 up, 0 down | May 11, 2023 | $10.55M |
| Dec 31, 2022 | -$0.31 | -$0.41 | N/A | +24.39% | Beat | N/A | 4 | 0 up, 0 down | Feb 23, 2023 | $9.46M |
| Sep 30, 2022 | -$0.33 | -$0.51 | N/A | +35.29% | Beat | N/A | 4 | 0 up, 0 down | Nov 10, 2022 | $9.09M |
| Jun 30, 2022 | -$0.35 | -$0.57 | N/A | +38.60% | Beat | N/A | 4 | 4 up, 0 down | Aug 11, 2022 | $8.34M |
| Mar 31, 2022 | -$0.55 | -$0.52 | N/A | -5.77% | Miss | N/A | 3 | 0 up, 0 down | May 12, 2022 | $7.54M |
| Dec 31, 2021 | -$0.34 | -$0.37 | N/A | +7.76% | Beat | N/A | N/A | 0 up, 1 down | Feb 28, 2022 | $6.94M |
| Sep 30, 2021 | -$0.24 | -$0.38 | N/A | +36.84% | Beat | N/A | 4 | N/A | Nov 8, 2021 | $7.02M |
| Jun 30, 2021 | -$0.17 | -$0.29 | -$0.40 - -$0.20 | +41.38% | Beat | N/A | 4 | N/A | Aug 26, 2021 | $10.30M |
| Mar 31, 2021 | -$0.34 | -$0.50 | N/A | +32.00% | Beat | N/A | 4 | N/A | May 13, 2021 | $7.02M |
| Dec 31, 2020 | -$0.34 | -$0.59 | N/A | +42.37% | Beat | N/A | 4 | N/A | Feb 11, 2021 | $10.30M |
| Sep 30, 2020 | -$0.66 | -$0.49 | -$0.57 - -$0.13 | -34.69% | Miss | N/A | 4 | N/A | Nov 10, 2020 | $5.06M |
| Jun 30, 2020 | -$0.60 | -$0.24 | N/A | -150.00% | Miss | N/A | N/A | N/A | Aug 27, 2020 | $3.88M |
| Mar 31, 2020 | -$0.71 | -$0.09 | -$0.12 - $0.00 | -688.89% | Miss | N/A | 3 | N/A | Apr 29, 2020 | $3.88M |
| Dec 31, 2019 | -$0.07 | -$0.03 | N/A | -120.67% | Miss | N/A | N/A | N/A | Feb 18, 2020 | $3.26M |
| Sep 30, 2019 | Not reported | -$0.14 | N/A | N/A | Not reported | N/A | N/A | N/A | Oct 31, 2019 | $3.25M |
| Jun 30, 2019 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Aug 29, 2019 | $2.99M |
| Mar 31, 2019 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | May 21, 2019 | $2.95M |
| Dec 31, 2018 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Feb 27, 2019 | $826559 |
| Sep 30, 2018 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Oct 30, 2018 | $906618 |
| Jun 30, 2018 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Aug 30, 2018 | $354280 |
| Mar 31, 2018 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Apr 29, 2018 | $295791 |
| Dec 31, 2017 | Not reported | N/A | N/A | N/A | Not reported | N/A | N/A | N/A | Jan 30, 2018 | $308201 |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$2.46, after -$3.33 the year before. It was -$0.07 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years below with reported EPS.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$2.46 | N/A |
| Dec 31, 2024 | -$3.33 | N/A |
| Dec 31, 2023 | -$2.14 | N/A |
| Dec 31, 2022 | -$1.54 | N/A |
| Dec 31, 2021 | -$1.09 | N/A |
| Dec 31, 2020 | -$2.31 | N/A |
| Dec 31, 2019 | -$0.07 | N/A |
| Dec 31, 2018 | Not reported | N/A |
| Dec 31, 2017 | Not reported | N/A |
Earnings Calls
The 8 most recent earnings calls are listed below; the latest, 2026Q3 for the period ended Sep 30, 2026, runs about 4,600 words across 6 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2026Q3 | Sep 30, 2026 | 4,571 | 6 | |
| 2026Q2 | Jun 30, 2026 | 3,335 | 7 | |
| 2026Q1 | Mar 31, 2026 | 4,046 | 8 | |
| 2025Q4 | Dec 31, 2025 | 3,891 | 7 | |
| 2025Q3 | Sep 30, 2025 | 4,731 | 7 | |
| 2025Q2 | Jun 30, 2025 | 5,907 | 7 | |
| 2025Q1 | Mar 31, 2025 | 4,264 | 7 | |
| 2024Q4 | Dec 31, 2024 | 5,821 | 8 |
2026Q3 Earnings Call
Opening remarks
Ben Atkins Vice President of Investor Relations Thank you, operator. Welcome to AVITA Medical's Third Quarter 2026 Earnings Call. Joining me on today's call are Cary Vance, President and Chief Executive Officer, and David O'Toole, Chief Financial Officer. Today's earnings release and presentation are available on our website at www.avitamedical.com under the Investor Relations section. Before we begin, I would like to remind you that this call includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements are neither promises nor guarantees and involve known and unknown risks and uncertainties that could cause actual results to differ materially from any expectations expressed or implied by the forward-looking statements. Please review our most recent filings with the SEC for comprehensive descriptions of the risk factors. Any forward-looking statements provided during this call are based on management's expectations as of today. I will now turn the call over to Cary.
Cary Vance President and Chief Executive Officer Good afternoon in the U.S. and good morning in Australia. As always, we appreciate you making the time to join us on our quarterly update call. Before I discuss the quarter, I want to acknowledge the clinicians caring for patients with serious burn injuries following the devastating fire at the Wainwright Military Base in Alberta, Canada. At their request, we mobilized quickly. We donated about three dozen RECELL units to burn centers in Calgary and Edmonton and sent AVITA staff to train and to support the clinical teams. Within days, the first patient received treatment with RECELL. Serious burn injuries can happen without warning. Responding takes preparation, access to treatment, and people ready to act. I want to thank our team, the clinicians and burn community in Canada, and the American Burn Association for connecting us. RECELL is not commercially available in Canada, and we are grateful to Health Canada for acting quickly to facilitate access. This response brings us back to why we do this work, helping people heal from serious wounds and return to their lives. Let me turn to our third quarter performance. Revenue reached $26.1 million, up 53% year-over-year and 20% from the second quarter. RECELL led that growth, supported by increasing adoption of Cohealyx. We will further discuss our product dynamics in a moment. At the same time, we reduced cash use to approximately $600,000 compared with $3.2 million in Q2. We are growing revenue, but we are also managing expenses and cash diligently. That combination continues to improve the financial position of the company. Based on our performance, we are raising full-year revenue guidance for the second consecutive quarter. We now expect revenue of $92 million-$94 million for the full year, compared with our previous range of $86 million-$89 million.
Frequently Asked Questions About RCEL
When is Avita Medical's next earnings date?
Avita Medical's next earnings report is expected for Feb 10, 2027.
Did RCEL beat earnings estimates last quarter?
Yes. Avita Medical reported EPS of -$0.20 for the quarter ended Sep 30, 2026, above the -$0.29 estimate, a 31.03% surprise.
What EPS do analysts expect from RCEL next quarter?
The consensus EPS estimate for Avita Medical for the quarter ending Dec 31, 2026 is -$0.20 from 6 analysts, with estimates from -$0.22 to -$0.18.
How often does RCEL beat earnings estimates?
Avita Medical beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of -14.78%.
RCEL pages: Overview, Earnings, Forecast, Competitors